Executive Management

Dr. Vincent Mutel, CEO, co-founder and member of the BoD, was co-founder, CEO and vice chairman of the board of Addex Pharmaceuticals Ltd, a well-established public Swiss biotech, and prior was Research Area Head in the CNS division at the Swiss pharmaceutical company F. Hoffmann-La Roche Ltd where he worked for 13 years. Vincent is a biochemist and pharmacologist by training and has initiated and successfully driven several R&D projects bringing molecules from discovery to advanced clinical trial. In his role at Addex Pharmaceuticals Ltd he led the growth of the organization to up to 140 staff, completed three rounds of venture financing, an IPO and a PIPE, totaling CHF263 million, and signed three major drug development partnerships, two with Merck & Co., Inc. and one with Ortho-McNeil-Janssen Pharmaceuticals Inc., a Johnson & Johnson company, representing CHF43 million in realized revenues.

Dr. Andrea Cesura, CSO, is a pharmacologist with more than 25 years of experience in research and drug development in Pharmaceutical and Biotech companies with a track record of several compounds which entered clinical development. Andrea has previously held positions as SVP Preclinical Research at Evotec, where he was responsible for building and advancing the company proprietary CNS R&D pipeline, Associate Director at Serono and Senior Scientist at Hoffmann-La Roche. Andrea’s experience spans from discovery to clinical development and has initiated and led several projects on inflammatory disorders. Andrea holds a PhD in Physiological and Pharmacological Sciences from the University of Milan.

Dr. Eduard Vidovic, CMO, is a medical doctor with 10 years of practicing clinical experience and over 15 years of clinical research and development experience focusing on chronic inflammatory diseases, having held medical leadership roles in global Pharmaceutical and Biotech companies such as Synthelabo Pharma, Sanofi-Aventis and more recently Creabilis SA. His industrial experience spans over early to late stage development and medical affairs. As a CMO of Creabilis he was leading the development of several dermatology drugs in Atopic Dermatitis, Psoriasis, and chronic Pruritus. With significant operating and team leadership experience from organizations with diverse cultures and operating environments he was dealing with the FDA and regulatory authorities in Europe, successfully bringing drug candidates through the different phase of development process. Eduard received his medical degree from Zagreb University and his Ph.D. from the University of Geneva. He also holds a specialist FMH degree in Pharmaceutical Medicine. Earlier in his career, Dr. Vidovic was a Senior House Officer at the University Cantonal Hospital in Geneva and a Consultant at La Tour Hospital, Switzerland.

Dr. Cyril Portmann, Head of Chemistry, is an expert in Natural Product Chemistry holding a Ph.D. from EPFL in Lausanne and Post-Doctoral training at Harvard Medical School in Boston. During his career, Dr. Portmann acquired several years of experience in the area of discovery of new bioactive small molecules from natural origins for different indications like malaria and cancer. Dr. Portmann has published 13 scientific peer-reviewed publications in journals such as PNAS.